IONS News and Press, Ionis Pharmaceuticals Inc. From 10/16/23

2023-10-16 05:59:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Stock selection has be...

2023-10-13 18:11:38 ET Summary We rate Alnylam Pharmaceuticals, Inc.'s common stock a Buy on the dip after the complete response letter, CRL for Patisiran. The investment thesis is based on the high probability of success for Vutrisiran, the company's next-generation inverse RNA o...

2023-10-10 18:08:45 ET Summary Despite a positive panel recommendation, the FDA rejected the Alnylam Pharmaceuticals, Inc. application to market Onpattro for ATTR-CM, citing a lack of meaningful evidence of clinical efficacy. Amvuttra has always been the bigger opportunity in ATTR...

Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization PR Newswire With experienced commercial team in place, Ionis poised to independently bring steady cadence o...

2023-10-02 14:25:11 ET More on Praxis Precision Medicines Praxis Precision Medicines: Long List Of Failures And Mixed Data Praxis Precision Meds up 9% on new Truist buy rating Larimar, Design higher as they benefit from Biogen deal for Reata Seeking Alpha...

Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 (Essential3) program for ulixacaltamide initiating this quarter with mADL11 as primary endpoint; nearly 600 patie...

2023-09-29 15:00:29 ET More on the markets Historical Evidence Between Real Yields Suggests Further Slump For SPY Interest Rates Won't Be Higher For Longer: SPY Implications Rate environment today 'rhymes with 2008' - J.P. Morgan's Kolanovic Stocks in midst o...

2023-09-29 13:05:39 ET More on AbbVie, Alnylam, etc. AbbVie: Company Vs. Stock, A Gentle Facelift Would Be Nice (Technical Analysis) AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemoths AbbVie Inc. (ABBV) Morgan Stanley 21st Annual Global Healthcare Brokers...

Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit PR Newswire Publication of NEURO-TTRansform study in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen halted disease progression and contin...

2023-09-27 10:25:40 ET More on Ionis Pharmaceuticals, Roche Roche: Positive Readouts From Pipeline Roche: 2023 Should Mark The Bottom Ionis Pharmaceuticals: Mid-Sized Pharma Is A Strong Buy Opportunity For All-Comers Ionis late-stage rare disease data fails t...